Tausif  Butt net worth and biography

Tausif Butt Biography and Net Worth

COO of ChemoCentryx
Mr. Butt has served as our Executive Vice President and Chief Operating Officer since February 2021. Prior to joining us, Mr. Butt served as the Senior Vice President of Latin America for AstraZeneca from 2019 to 2021 and U.S. Vice President, Respiratory from 2015 to 2018 and U.S. Vice President of Sales, Primary Care from 2014 to 2015. Prior to this, Mr. Butt held several marketing and sales leadership roles with GlaxoSmithKline from March 2000 to 2014 and from 1990 to 1993. He also worked in sales and marketing roles at Sanofi from 1993 to 2000. Mr. Butt began his career as a retail pharmacist, having received a degree in Pharmacy from the University of Brighton in the United Kingdom. He also holds an MSc in Management from Imperial College, University of London.

What is Tausif Butt's net worth?

The estimated net worth of Tausif Butt is at least $565,131.30 as of May 7th, 2021. Mr. Butt owns 10,870 shares of ChemoCentryx stock worth more than $565,131 as of March 28th. This net worth evaluation does not reflect any other investments that Mr. Butt may own. Additionally, Mr. Butt receives an annual salary of $1,010,000.00 as COO at ChemoCentryx. Learn More about Tausif Butt's net worth.

How old is Tausif Butt?

Mr. Butt is currently 56 years old. There are 5 older executives and no younger executives at ChemoCentryx. The oldest executive at ChemoCentryx is Dr. Thomas J. Schall Ph.D., Founder, Pres, CEO & Chairman, who is 63 years old. Learn More on Tausif Butt's age.

What is Tausif Butt's salary?

As the COO of ChemoCentryx, Inc., Mr. Butt earns $1,010,000.00 per year. The highest earning executive at ChemoCentryx is Dr. Thomas J. Schall Ph.D., Founder, Pres, CEO & Chairman, who commands a salary of $1,210,000.00 per year. Learn More on Tausif Butt's salary.

How do I contact Tausif Butt?

The corporate mailing address for Mr. Butt and other ChemoCentryx executives is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. ChemoCentryx can also be reached via phone at (650) 210-2900 and via email at [email protected]. Learn More on Tausif Butt's contact information.

Has Tausif Butt been buying or selling shares of ChemoCentryx?

Tausif Butt has not been actively trading shares of ChemoCentryx within the last three months. Most recently, on Friday, May 7th, Tausif Butt bought 10,870 shares of ChemoCentryx stock. The stock was acquired at an average cost of $11.06 per share, with a total value of $120,222.20. Following the completion of the transaction, the chief operating officer now directly owns 10,870 shares of the company's stock, valued at $120,222.20. Learn More on Tausif Butt's trading history.

Who are ChemoCentryx's active insiders?

ChemoCentryx's insider roster includes Tausif Butt (COO), Markus Cappel (Treasurer), Thomas Edwards (Director), Susan Kanaya (CFO), Geoffrey Parker (Director), Thomas Schall (CEO), and James Tyree (Director). Learn More on ChemoCentryx's active insiders.

Tausif Butt Insider Trading History at ChemoCentryx

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/7/2021Buy10,870$11.06$120,222.2010,870View SEC Filing Icon  
See Full Table

Tausif Butt Buying and Selling Activity at ChemoCentryx

This chart shows Tausif Butt's buying and selling at ChemoCentryx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

ChemoCentryx Company Overview

ChemoCentryx logo
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.
Read More

Today's Range

Now: $51.99
Low: $51.99
High: $51.99

50 Day Range

MA: $51.95
Low: $51.66
High: $51.99

2 Week Range

Now: $51.99
Low: $14.95
High: $52.00

Volume

113 shs

Average Volume

1,681,906 shs

Market Capitalization

$3.71 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22